EP08.02-034 OCELOT - Osimertinib then Chemotherapy in EGFR+ Lung Cancer with Osi Third-line Rechallenge and Osimertinib for Uncommon EGFRm in 1L Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Breadner, D
  • Liu, G
  • Rothenstein, J
  • Wheatley-Price, P
  • Bains, P
  • Cheng, S
  • Wang, Y
  • Sun, S
  • Mithoowani, H
  • Juergens, Rosalyn
  • Cheema, P
  • Vincent, M

publication date

  • September 2022